Dr Pravin D Potdar, Faculty, Indian Dental Association Research Fellowship Program
Single nucleotide polymorphisms (SNPs) are extensively used to analyze characteristics of individual who can respond to a therapeutic agent. NGS technology is useful for large-scale screening of SNPs to determine whether new drug will be effective and safe in respective individual. Large amount of genomic sequence data obtained by NGS will allow scientists to develop novel therapeutic agents by studying specific mechanism of respective disease. This is mainly important for genetic disorders which are difficult to diagnose. NGS allows us to screen and profile large number of gene mutations involved in particular diseases in short period of time and thus unique biomarkers are identified to discover drug targets. The major goal of NGS is to developed molecular targeted therapies for cancer which kill tumour cells without harming normal cell growth resulting into reduction in side effect and thus the mortality. The identification of novel molecular targets, biomarkers, and mechanistic information by NGS fastens the drug discovery process in recent year.
Recent forecast across North America, Europe, Asia-Pacific, and the Rest of the World, the global NGS services market is expected to be doubled in next five years. In year 2017, it is almost USD 1.059 billion and will reach to USD 2.74 billion by 2022. North America accounted for the largest share followed by Europe. Due to the rapid growth in the genomic research and NGS based diagnostics in emerging Asia-Pacific countries, like China and India, will adopt more NGS services in near future.